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Abstract Cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy (CADASIL)
is an inherited disease of small arteries caused by mutations
in the Notch3 gene. Complex migrainous episodes, such as
acute confusional migraine, status migrainosus with per-
sisting aura, and ‘‘CADASIL coma’’ have been described in
patients with CADASIL. However, there are few descrip-
tions of effective treatment of such episodes. We describe a
44-year-old male with CADASIL, who presented with
sudden-onset aphasia and decreased responsiveness after
prolonged,severemigraineattack.Subsequently,thepatient
hadtwogeneralizedseizures.Asubtlestatusepilepticuswas
suspected because of drowsiness and seizures, and intrave-
nous sodium valproate medication was initiated. EEG
recording showed left hemispheric attenuation but no spike
discharges, thus not conﬁrming epileptic mechanism. The
clinical status of the patient improved markedly after the
initiation of valproate. The patient started speaking again;
drowsiness and headache subsided. In repeated EEG
recording, the left hemispheric attenuation disappeared.
Diffusion weighted MR imaging showed no signs of recent
ischemic events. The patient recovered fully from the epi-
sode with no further seizures. We suggest that CADASIL
patients with acute complex migrainous episodes may
beneﬁt from intravenous sodium valproate.
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Introduction
Cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL) is an inher-
ited disease of small arteries caused by mutations in the
Notch3 gene [1, 2]. Complex migrainous manifestations,
such as acute confusional migraine (ACM) [3], status mi-
grainosus with persisting aura [4] and a more severe man-
ifestation, the so-called ‘‘CADASIL coma’’ [5], have been
described in patients with CADASIL. However, there are
few reports on efﬁcacious treatment of such episodes. Some
patients with ‘‘CADASIL coma’’ have been treated with
intravenous (i.v.) phenytoin [5]. Sodium valproate is used
as both preventive and acute treatment of migraine. We
report ﬁrst successful treatment of an acute complex
migrainous episode in a patient with CADASIL using i.v.
valproate.
Case report
We describe a 44-year-old male with CADASIL, a member
of an identiﬁed CADASIL family. He had a conﬁrmed
R133C Notch3 mutation. The patient also had type 2 dia-
betes mellitus, hypercholesterolemia, obesity, and slightly
elevated blood pressure. Regular medications included
acetylsalicylic acid, bisoprolol, simvastatin, metformin,
glimepiride, and escitalopram. He had hemiplegic migraine
(ICHD-II classiﬁcation: 6.7.1; headache attributed to
CADASIL. As to the ICHD-II classiﬁcation of headache in
CADASIL, a revision has recently been suggested [6]).
Typical aura symptoms were right hemiparesis, confusion,
and aphasia, and the duration of the migraine attacks was
less than 1 day. There was no history of symptoms sug-
gestive of epilepsy.
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longed, severe migraine attack with onset 3 days earlier.
Initial clinical investigation showed global aphasia. Slight
right hemiparesis, which was an old ﬁnding, was noticed.
Flexor plantar responses were observed. The patient was
conscious but responsiveness was decreased. He was not
agitated. Body temperature, blood pressure and basic lab-
oratory investigations (including plasma sodium, potas-
sium, calcium, and free thyroxine) were normal. Plasma
glucose level was 8.1 mmol/l. Arterial blood gases, ketone
bodies, or magnesium or phosphate levels were not
investigated. Autoimmune thyroid studies were not per-
formed. There were no signs of meningeal irritation, and
lumbar puncture was not performed. The patient and his
family were known in the hospital, and nothing suggested
intoxication or substance abuse. Thus no toxicology screen
was performed. Brain CT (Fig. 1a) on admission to hos-
pital showed symmetric leukoaraiosis characteristic of
CADASIL and symmetric basal ganglia calciﬁcations, but
no new ﬁndings that would explain the acute symptoms.
Perfusion CT imaging was not performed.
Initially, the patient was thought to have suffered an
ischemic stroke, and he was admitted to neurological ward.
He remained conscious, but somewhat drowsy and aphasic.
Due to the patient’s aphasia, the persistence of headache
was difﬁcult to conﬁrm. On the second day in hospital he
had two brief generalized seizures. Because of drowsiness
and seizures, a subtle status epilepticus was suspected and
i.v. sodium valproate medication was initiated (ﬁrst a
loading dose of 800 mg i.v., the following day total
1,600 mg i.v. in three doses, 1,200 mg i.v. in two doses
daily thereafter). Short-time EEG recording performed on
the same day (before the initiation of valproate) showed left
hemispheric attenuation, but no spike discharges or epi-
leptic paroxysmal rhythmic activity. The clinical status of
the patient improved markedly after the initiation of val-
proate. The patient started speaking again, he became
responsive and drowsiness subsided. There were no further
seizures. In a repeated EEG recording the following day, the
left hemispheric attenuation disappeared. Brain MR imag-
ing (Fig. 1b, c) on third day in hospital showed symmetric
white matter ischemic lesions and basal ganglia calciﬁca-
tions in accordance with previous imaging ﬁndings. Diffu-
sion weighted MR imaging showed no signs of recent
ischemic events. MR angiography was normal. Perfusion
MR imaging, PET, or SPECT imaging were not performed.
The patient recovered fully from the episode with no further
seizures in the follow-up. He has not had similar, severe
migrainous episodes since. He has continued on a regular
peroral valproate medication, 600 mg twice daily.
Fig. 1 a Conﬂuent symmetric leukoaraiosis typical of CADASIL on
admission head CT. b Fluid-attenuated inversion recovery (FLAIR)
series in brain MR imaging showed old basal ganglia infarctions in
addition to extensive white matter hyperintensities. c Diffusion tensor
MR imaging showed no signs of acute ischemia
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There seems to be some clinical continuity or overlap in
several complex migrainous conditions described in
CADASIL patients. In ACM, the symptoms of prolonged
migraine with aura, impaired language functions and
decreased responsiveness, or confusion and agitation are
common [3]. A previously reported CADASIL patient with
status migrainosus had several clinical neurologic deﬁcits,
including psychomotor slowness, speech difﬁculties, and a
generalized seizure [4]. Among the six patients with
‘‘CADASIL coma’’ described in a previous work [5], the
episodes typically started with migraine attacks, other
common features being confusion, drowsiness, and other
neurologic deﬁcits. Four of these patients had seizures,
and three had been treated with i.v. phenytoin medication.
A previous CADASIL patient with non-convulsive status
epilepticus (NCSE) presented with psychomotor slowing,
confusion, left-sided neglect, and hemianopia [7]. The
symptoms of the patient were also precipitated by a pro-
longed, severe migraine, and she was treated with i.v.
phenytoin. There are, however, to our knowledge no pre-
vious reports on patients with CADASIL and migrainous
conditions or seizures treated with i.v. valproate.
Sodium valproate has been used extensively in migraine
prophylaxis, but its role in acute treatment of migraine is
less established. However, in a recent report [8] i.v. sodium
valproate was found to be effective in acute migraine
treatment. Valproate has several mechanisms of action that
explain its anti-migraine effects, including the increase of
c-aminobutyric acid (GABA) levels in the brain and the
reduction of ﬁring rates of serotonergic cells in dorsal
raphe [8]. Interestingly, ﬁndings of another recent study [9]
suggested that valproate might have beneﬁcial effects in
CADASIL via cytoprotective effects on vascular smooth
muscle cells.
The clinical features of our patient are compatible with
a complex migrainous episode in CADASIL. The presenta-
tion of severe aura symptoms (aphasia) after the onset
of migrainous headache is unusual, but this may be the
case in CADASIL. Typically these episodes present
after a prolonged migraine with symptoms of decreased
responsiveness, confusion, language difﬁculties, focal neu-
rologic deﬁcits such as hemianopia or hemiparesis, and
sometimes seizures. The patient showed deﬁnite clinical
response to i.v. sodium valproate medication. We suggest
that in CADASIL patients with acute, complex migrainous
episodes, i.v. sodium valproate may be a good therapeutic
option.
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